Sutro Biopharma, Inc. (STRO) Stock Price

STROStock

$10.94+24.18%52W

Market Cap$181.40M

P/E—

PEG Ratio—

Div yield—

Beta1.49

STRO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-71.89%

Price vs S&P 500 (4W)-31.76%

VGM Score38.62

Book Value / Share (Quarterly)$0.53

P/TBV (Annual)0.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.78%

Cash Flow / Share (Quarterly)$-8.78

Price vs S&P 500 (YTD)-17.37%

Net Profit Margin (TTM)-395.25%

EPS (TTM)$-17.32

10-Day Avg Trading Volume0.33M

EPS Excl Extra (TTM)$-17.32

Revenue Growth (5Y)19.13%

EPS (Annual)$-22.49

ROI (Annual)-100.91%

Net Profit Margin (5Y Avg)-193.80%

Cash / Share (Quarterly)$9.91

Revenue Growth QoQ (YoY)-84.57%

ROA (Last FY)-109.93%

Revenue Growth TTM (YoY)-56.25%

EBITD / Share (TTM)$-11.95

ROE (5Y Avg)-137.55%

Operating Margin (TTM)-319.57%

Cash Flow / Share (Annual)$-20.84

P/B Ratio4.12x

P/B Ratio (Quarterly)3.45x

Net Income / Employee (Annual)$-1,394,800

EV / Revenue (TTM)8.01x

Net Interest Coverage (TTM)-14.06x

ROA (TTM)-88.12%

EPS Incl Extra (Annual)$-22.49

Current Ratio (Annual)2.01x

Quick Ratio (Quarterly)3.22x

3-Month Avg Trading Volume0.34M

52-Week Price Return24.18%

Revenue / Employee (TTM)$333,600

Tangible BV / Share (Quarterly)$1.84

P/S Ratio (Annual)1.77x

Asset Turnover (Annual)0.59x

52-Week High$43.85

Operating Margin (5Y Avg)-189.28%

EPS Excl Extra (Annual)$-22.49

CapEx CAGR (5Y)-24.97%

26-Week Price Return-61.99%

Quick Ratio (Annual)1.94x

13-Week Price Return-53.59%

Total Debt / Equity (Annual)4.05x

Current Ratio (Quarterly)3.32x

Enterprise Value$366.13M

Revenue / Share Growth (5Y)55.85%

Asset Turnover (TTM)0.22x

Book Value / Share Growth (5Y)5.00%

Revenue / Employee (Annual)$748,100

Pretax Margin (Annual)-186.55%

Cash / Share (Annual)$16.48

3-Month Return Std Dev69.69%

Net Income / Employee (TTM)$-1,318,500

ROE (Last FY)-509.99%

Net Interest Coverage (Annual)-5.34x

EPS Basic Excl Extra (Annual)$-22.49

P/FCF (TTM)8.39x

Receivables Turnover (TTM)6.63x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-17.32

Receivables Turnover (Annual)16.28x

ROI (TTM)-223.84%

P/S Ratio (TTM)3.97x

Pretax Margin (5Y Avg)-189.95%

Revenue / Share (Annual)$12.06

Tangible BV / Share (Annual)$3.77

Price vs S&P 500 (52W)8.65%

Year-to-Date Return-5.45%

5-Day Price Return-17.62%

EPS Normalized (Annual)$-22.49

ROA (5Y Avg)-50.31%

Net Profit Margin (Annual)-186.45%

Month-to-Date Return-32.09%

Cash Flow / Share (TTM)$-2.80

EBITD / Share (Annual)$-17.77

Operating Margin (Annual)-154.53%

LT Debt / Equity (Annual)4.05x

ROI (5Y Avg)-46.86%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-17.32

P/TBV (Quarterly)1.33x

P/B Ratio (Annual)3.40x

Pretax Margin (TTM)-395.46%

Book Value / Share (Annual)$5.40

Price vs S&P 500 (13W)-56.27%

Beta1.49x

P/FCF (Annual)16.31x

Revenue / Share (TTM)$2.76

ROE (TTM)-223.84%

52-Week Low$7.15

vGradeC

gGradeD

mGradeD

vgmGradeD

STRO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$2.29	-$2.31	-1.01%(-$0.02)
Q1 2026	May 14, 2026	-$3.21	-$2.94	+8.60%(+$0.28)
Q4 2025	Mar 23, 2026	-$4.43	-$4.88	-10.24%(-$0.45)
Q3 2025	Nov 6, 2025	-$3.55	-$5.57	-56.99%(-$2.02)
Q2 2025	Aug 7, 2025	-$3.82	-$1.40	+63.39%(+$2.42)

STRO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.10

4.11

4.15

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
STROSutro Biopharma, Inc.	C	D	D	4.0x	-56.3%	—	—	$10.94
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Sutro Biopharma, Inc.

Sutro Biopharma is a clinical-stage biopharmaceutical company developing protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF cell-free protein synthesis platform. Lead programs include STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers, with additional candidates in development.